大剂量阿糖胞苷巩固治疗急性髓系白血病患者的效果  

Effect of high-dose cytarabine consolidation therapy on patients with acute myeloid leukemia

作　　者：武玉慧 WU Yuhui(Department of Hematology of Xinyang Central Hospital,Xinyang 464000 Henan,China)

机构地区：[1]信阳市中心医院血液科,河南信阳464000

出　　处：《中国民康医学》2023年第15期28-31,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察大剂量阿糖胞苷巩固治疗急性髓系白血病患者的效果。方法:选取2017年7月至2020年8月该院收治的117例急性髓系白血病患者进行前瞻性研究,采用随机数字表法将其分为对照组(n=58)和研究组(n=59)。两组均进行诱导化疗,在此基础上,对照组采用2 g/(m^(2)·12 h)阿糖胞苷巩固治疗,研究组采用3 g/(m^(2)·12 h)阿糖胞苷巩固治疗,比较两组远期临床疗效、治疗前后T细胞亚群指标水平、治疗期间不良反应发生率和生命质量[世界卫生组织生活质量简表(WHOQOL-BREF)]评分。结果:研究组疾病控制率为94.92%(56/59),高于对照组的79.31%(46/58),差异有统计学意义(P<0.05);治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高^(+)于治疗前,CD8水平均低于治疗前,但组间比较,差异无统计学意义(P>0.05);两组胃肠道反应、感染、骨髓抑制和皮肤反应等不良反应发生率比较,差异均无统计学意义(P>0.05);治疗后,两组生理领域、心理领域、独立性领域、环境领域WHOQOL-BREF评分及总分均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05)。结论:大剂量阿糖胞苷巩固治疗急性髓系白血病患者可提高疾病控制率和生命质量评分,效果优于常规剂量阿糖胞苷巩固治疗。Objective:Observation of the effect of high-dose cytarabine consolidation therapy on patients with acute myeloid leukemia.Methods:A prospective study was conducted on 117 patients with acute myeloid leukemia admitted to the hospital from July 2017 to August 2020.They were divided into control group(n=58)and study group(n=59)by using the random number table method.Both groups received induction chemotherapy.On this basis,the control group was treated with 2 g/(m^(2)·12 h)Cytarabine consolidation therapy,while the study group was treated with 3 g/(m^(2)·12 h)Cytarabine consolidation therapy.The long-term clinical efficacy,the levels of T cell subsets before and after the treatment,the incidence of adverse reactions during the treatment,and the quality of life[World Health Organization quality of life-BREF(WHOQOL-BREF)]score were compared between the two groups.Results:The disease control rate of the study group was 94.92%(56/59),which was higher than 79.31%(46/58)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in^(+)both groups were higher than those before the treatment,while the levels of CD8 were lower than those before the treatment;however,there was no statistically significant difference between the groups(P>0.05).There were no significant differences between the two groups in the incidence of gastrointestinal reaction,infection,bone marrow suppression,skin reaction and other adverse reactions(P>0.05).Further,after the treatment,the WHOQOL-BREF scores in the physiological,psychological,independence,environmental domains and total scores of the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusions:High-dose Cytarabine can improve the disease control rate and the quality of life score in the patients with acute myeloid leukemia.Moreover,it is superior to conventional dose of

关 键 词：急性髓系白血病 剂量 阿糖胞苷 巩固治疗 疾病控制率 生命质量 T细胞亚群 

分 类 号：R733.71[医药卫生—肿瘤]